SUBSCRIBE
SUBSCRIBE

GLP-1

Biotech Beach
Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues for the Treatment of Inborn Errors of Metabolism at The Liver Meeting 2017 (AASLD)
This data will be presented by Vaidehi Joshi, Scientist I, Therapeutics, at Organovo.
October 20, 2017
 · 
7 min read
A Novo Nordisk flag flies in the wind/Courtesy jor
FDA
Eli Lilly Looks Over Its Shoulder After Novo Nordisk Wins FDA Panel Backing for Diabetes Drug
An advisory panel with the FDA gave a near unanimous support to Novo Nordisk’s diabetes drug semaglutide, a long-acting GLP-1 analogue.
October 19, 2017
 · 
2 min read
 · 
Alex Keown
Ablynx Seals Nanobody R&D Deal Worth $2.8 Billion With Drug Giant Sanofi
Business
Sanofi R&D Boss Thinks His Team is Ready to Survive Without Besties Regeneron and Alnylam
September 21, 2017
 · 
2 min read
Harmony Biosciences Gains U.S. Rights to Pitolisant, Raises $270 Million
Business
Biotech Gene Therapy Startup Apic Bio Launches in Cambridge, Massachusetts
August 22, 2017
 · 
2 min read
Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
Drug Development
Novo Nordisk A/S’s Diabetes Drug Beats Out Eli Lilly’s Trulicity in Phase III Trials
August 17, 2017
 · 
2 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
Galapagos’ Phase II Results With GLPG1690 are ‘Extremely Exciting’
August 10, 2017
 · 
2 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
Business
Dimension Therapeutics Pink Slips 25% of Workforce
June 27, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Business
Fast-Growing Intarcia Awaits Crucial FDA Decision in New Boston HQ
May 8, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Deals
PE Firm in Talks to Buy VWR in Deal Worth $5 Billion
May 4, 2017
 · 
2 min read
Top 5 Jobs for Introverted Life Scientists
Biotech Bay
Top 5 Jobs for Introverted Life Scientists
May 1, 2017
 · 
6 min read
Load More
PRESS RELEASES
Press Releases
Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
August 29, 2025
 · 
10 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
August 26, 2025
 · 
11 min read
Press Releases
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
August 20, 2025
 · 
7 min read
Press Releases
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
August 19, 2025
 · 
15 min read
Press Releases
Echosens and Novo Nordisk Advance Partnership to Increase Awareness and Early Diagnosis of MASH
August 18, 2025
 · 
3 min read
Press Releases
BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
August 18, 2025
 · 
7 min read
Press Releases
Ascletis Announces the Combination of ASC47 and ASC31, its Dual GLP-1R/GIPR Peptide Agonist, Demonstrated Significantly Greater Weight Loss Compared to the Combination of ASC47 and Tirzepatide in an Animal Model of Obesity
August 18, 2025
 · 
3 min read
Press Releases
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 14, 2025
 · 
11 min read
Press Releases
Response Pharmaceuticals Announces Positive Top-Line Results From Phase 2 Study of RDX-002 in Post-GLP-1 Management
August 14, 2025
 · 
6 min read
Press Releases
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy
August 13, 2025
 · 
8 min read
Press Releases
Lilly’s oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
August 7, 2025
 · 
10 min read
Press Releases
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
August 6, 2025
 · 
3 min read
Press Releases
Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115
August 6, 2025
 · 
8 min read
Press Releases
Biomea Fusion Reports Second Quarter 2025 Financial Results and Corporate Highlights
August 6, 2025
 · 
12 min read
Press Releases
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
August 6, 2025
 · 
5 min read
Press Releases
Allurion Announces New Strategic Direction With Increasing Focus on Low-Dose GLP-1 Combination Therapy, Muscle Mass Maintenance, and US Market Entry
August 5, 2025
 · 
9 min read
Press Releases
Noom Launches Microdose GLP-1 Program, Enabling Weight Loss Without the Side Effects and Priced at $119 to Start, Including Medication and Microhabits Program
August 5, 2025
 · 
8 min read
Press Releases
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
August 5, 2025
 · 
5 min read
Press Releases
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
July 30, 2025
 · 
7 min read
Press Releases
Hohenstein Medical Earns GLP Certification for Medical Device Testing
July 30, 2025
 · 
3 min read
Load More